Anti-PD-1 (RMP1-14)

Product Specifications

Background

CD279, also known as programmed death-1 (PD-1) is a 50-55 kD immunoglobulin superfamily member. PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily. This RMP1-14 antibody has been reported to block the binding of PD-1 to its ligands (B7-H1 and B7-DC) and to inhibit T cell proliferation and cytokine production.

Product Name Alternative

Programmed cell death protein 1, Pdcd1, CD279

UniProt

Q02242

Host

Rat

Reactivity

Mouse

Immunogen

Mouse PD-1 transfected BHK cells

Target

PD-1

Isotype

IgG2a κ

Clone

RMP1-14

Applications

Western Blot, Blocking, Flow Cytometry, Functional Assays

Purification Method

This monoclonal antibody was purified using Protein G

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Shipping Conditions

Blue ice

Storage Conditions

Anti-PD-1 In Vivo Antibody - Low Endotoxin (RMP1-14) is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -70oC.

Related Products

Anti-PD-1 In Vivo Antibody - Ultra Low Endotoxin [RMP1-14] (ICH1132UL)

Specificity

Anti-PD-1 In Vivo Antibody - Low Endotoxin (RMP1-14) recognizes an epitope on Mouse PD-1

Formulation

0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.

Antigen Distribution

Subset of double negative thymocytes, activated T and B cells

Aggregation

Aggregation level ≤ 5%

Applications Notes

Blocking: Clone RMP1-14 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1. For immune checkpoint antibodies 200 ug per mouse per injection is the standard dosage in the literature. For this anti-PD-1 (clone RMP1-14), we suggest to inject 200 ug/mouse ip generally on days 3, 6 and 9, post injection of tumor. Sometime up to six injections depending on the length of the experiment may be required. Each investigator should determine their own optimal working dilution for specific applications.